🇺🇸 FDA
Pipeline program

BXCL701

STUDY00005453

Phase 2 small_molecule active

Quick answer

BXCL701 for Metastatic Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
BioXcel Therapeutics
Indication
Metastatic Pancreatic Ductal Adenocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials